Informix

Atherosclerosis and atherothrombotic (acute thrombosis that develops in the presence of atherosclerosis) are the main pathological processes underlying the development of ischemic stroke (AI), coronary heart disease (CHD) and peripheral artery lesions. These processes have become the leading cause of death and disability in industrialized countries. According to statistical projections, by 2020 deaths from atherothrombotic complications may reach 25 million cases per year.
Currently there are about 20 antiplatelet agents, which, by the influence of the different units may block platelet aggregation, thereby stopping blood clots at an early stage. However, widespread clinical use as antiplatelet agents, proven effectiveness of large-scale, placebo-controlled studies, received the following drugs: acetylsalicylic acid (aspirin), ticlopidine and clopidogrel (Plavix).
Plavix is a potent inhibitor of clot formation. It operates on a common final path of platelet activation – ADP-induced conformational changes in the membrane of platelets, leading to the activation of IIb / IIIa glycoprotein and exhibiting opportunities for binding to fibrinogen.

According to one of the studies, Plavix is the only antiplatelet drug which has evident benefits over aspirin. It has been demonstrated tangible benefits of Plavix, compared with aspirin in preventing recurrent of atherothrombotic violations.
Currently, Plavix is used to prevent various ischemic disorders in patients with atherosclerosis, especially in patients with recent myocardial infarction or stroke, or have expressed the defeat of the peripheral arteries. Clopidogrel is also assigned to patients with acute coronary syndrome (unstable angina and myocardial infarction without tooth Q), including patients, subjected to conservative therapy or percutaneous intervention in coronary artery bypass.
Clinically proved data suggests that Plavix is not only normalizes platelet aggregation activity, but also stabilizes the intravascular hemostasis. Violation of the latter plays an important role in the syndrome of transient ischemia in patients with coronary artery disease of old age. The results showed that Plavix (unlike aspirin) improves the functional state of the endothelium, reduces blood viscosity and erythrocyte aggregation.